Lloyds Bank Commercial Banking supports Aesica Pharmaceuticals with working capital

Lloyds Bank Commercial Banking has supported Silverfleet Capital-backed Aesica Pharmaceuticals Ltd, a leading pharmaceutical development and manufacturing organisation

Aesica Pharmaceutical in Cramlington
Aesica Pharmaceuticals

Lloyds Bank Commercial Banking has supported Silverfleet Capital-backed Aesica Pharmaceuticals Ltd, a leading pharmaceutical development and manufacturing organisation.

The acquisition finance team acted as joint mandated lead arranger, as part of a banking syndicate, in providing a package of senior debt and working capital facilities.

Aesica Pharmaceuticals, headquartered in Newcastle, works closely with some of the world’s leading pharmaceutical companies to develop and manufacture active pharmaceutical ingredients and finished dosage forms across a range of markets.

With the backing of its banking partners, Aesica completed an extensive project to increase capacity at its manufacturing facilities in Kent to meet the global demands of its clients.

Neil Price, head of North of England, acquisition finance, Lloyds Bank Commercial Banking, said: “Since forging a relationship with Aesica in 2004, the company has built an enviable reputation on reliability, quality and excellence in customer service and become a leading contract manufacturing organisations in Europe.”

David Mackenzie, Silverfleet Capital principal, added: “The acquisition finance team at Lloyds has been a committed banking partner for Aesica since the buyout of the business. Its continued support will help lead the company through its next stage of growth.”

Journalists

David Whetstone
Culture Editor
Graeme Whitfield
Business Editor
Mark Douglas
Newcastle United Editor
Stuart Rayner
Sports Writer